Kura Oncology's (KURA) Market Outperform Rating Reiterated at JMP Securities

JMP Securities reaffirmed their market outperform rating on shares of Kura Oncology (NASDAQ:KURA - Free Report) in a research report report published on Wednesday morning,Benzinga reports. They currently have a $28.00 target price on the stock.

Other equities research analysts have also issued reports about the stock. Wedbush reiterated an "outperform" rating and issued a $36.00 target price on shares of Kura Oncology in a report on Tuesday, April 8th. Mizuho decreased their target price on Kura Oncology from $32.00 to $30.00 and set an "outperform" rating for the company in a research note on Monday, May 19th. Wall Street Zen downgraded Kura Oncology from a "buy" rating to a "hold" rating in a report on Friday, May 2nd. HC Wainwright reiterated a "buy" rating and set a $40.00 price objective on shares of Kura Oncology in a report on Monday, April 28th. Finally, BTIG Research downgraded shares of Kura Oncology from a "buy" rating to a "neutral" rating in a report on Thursday, February 6th. Four research analysts have rated the stock with a hold rating, nine have assigned a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $24.50.

Kura Oncology Trading Up 2.4%

Shares of NASDAQ:KURA traded up $0.16 during midday trading on Wednesday, hitting $6.73. The company had a trading volume of 765,456 shares, compared to its average volume of 1,217,613. The company has a current ratio of 11.47, a quick ratio of 11.47 and a debt-to-equity ratio of 0.02. Kura Oncology has a 12 month low of $5.41 and a 12 month high of $23.48. The firm has a fifty day simple moving average of $6.07 and a 200 day simple moving average of $7.63. The stock has a market cap of $582.65 million, a price-to-earnings ratio of -2.85 and a beta of 0.40.

Kura Oncology (NASDAQ:KURA - Get Free Report) last issued its earnings results on Thursday, May 1st. The company reported ($0.66) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.15). The business had revenue of $14.11 million during the quarter, compared to analysts' expectations of $39.08 million. On average, analysts predict that Kura Oncology will post -2.44 EPS for the current year.

Hedge Funds Weigh In On Kura Oncology

Hedge funds have recently modified their holdings of the stock. Virtus ETF Advisers LLC grew its stake in Kura Oncology by 71.6% in the fourth quarter. Virtus ETF Advisers LLC now owns 7,336 shares of the company's stock valued at $64,000 after purchasing an additional 3,061 shares in the last quarter. State of Wyoming bought a new position in shares of Kura Oncology in the first quarter valued at $48,000. Harbor Advisors LLC acquired a new position in Kura Oncology during the fourth quarter worth $87,000. Pallas Capital Advisors LLC acquired a new position in Kura Oncology during the first quarter worth $66,000. Finally, E Fund Management Co. Ltd. bought a new stake in Kura Oncology during the fourth quarter worth $90,000.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.